Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
HBV cccDNA: The Molecular Reservoir of Hepatitis B Persistence and Challenges to Achieve Viral Eradication.
Biomolecules
January 2025
Department of Gastroenterology and Hepatology, Erasmus Medical Center, Wytemaweg 80, 3015CN Rotterdam, The Netherlands.
Hepatitis B virus (HBV) is a major global health issue, with an estimated 254 million people living with chronic HBV infection worldwide as of 2022. Chronic HBV infection is the leading cause of cirrhosis and liver cancer. Current treatment with nucleos(t)ide analogs is effective in the suppression of viral activity but generally requires lifelong treatment.
View Article and Find Full Text PDFinfection in captive non-human primates in zoological gardens in Spain.
J Helminthol
January 2025
Department of Microbiology and Parasitology, Faculty of Pharmacy, University of Seville, Seville, Spain.
Currently, there is limited available information on the epidemiology of parasitic infections in captive non-human primates (NHPs) and their zoonotic potential. However, numerous cases of helminth infections in NHPs have been documented in several zoos around the world, with one of the most prevalent being those of the genus The main objective of this study is to investigate the occurrence of infection by spp. in primates from zoological gardens in Spain and to ascertain, at the species level, the specific species harbored by these hosts by using mitochondrial and ribosomal markers.
View Article and Find Full Text PDFBehavioral medicine in the GLP-1 era.
Ann Behav Med
December 2024
Department of Psychology, University of California, Los Angeles, Los Angeles, CA 90095, United States.
Glucagon-like peptide-1 (GLP-1) agonist medications are receiving high levels of attention because of their dramatic efficacy in causing weight loss. This commentary discusses several ways that those in behavioral medicine and health psychology might think about these medications-whether they should be fully in support of them or whether they pose a risk. The positive aspects of GLP-1s include their great promise in improving health independent of weight loss and the perspective that their efficacy frees individuals from the difficulties of behavioral weight maintenance and the associated stigma of "failing" to lose weight.
View Article and Find Full Text PDFBoosting antitumor immunity in breast cancers: Potential of adjuvants, drugs, and nanocarriers.
Int Rev Immunol
November 2024
Pharmacy Department, Zibo Central Hospital, Zibo, Shandong, China.
Despite advancements in breast cancer treatment, therapeutic resistance, and tumor recurrence continue to pose formidable challenges. Therefore, a deep knowledge of the intricate interplay between the tumor and the immune system is necessary. In the pursuit of combating breast cancer, the awakening of antitumor immunity has been proposed as a compelling avenue.
View Article and Find Full Text PDFA stochastic population model for the impact of cancer cell dormancy on therapy success.
J Theor Biol
January 2025
Department of Computer Science and Information Theory, Budapest University of Technology and Economics, Műegyetem rkp. 3, H-1111 Budapest, Hungary. Electronic address:
Article Synopsis
- Therapy evasion and disease progression in oncology are significantly impacted by cancer cell dormancy, which can hinder treatments like chemotherapy and lead to relapses long after initial success.
- The paper presents a mathematical model that simulates how individual cancer cells can switch between active and dormant states, examining the effects of various drug treatments on these dynamics.
- Results indicate that even a small number of dormant cells can cause traditional single-drug therapies to fail, and the study offers insights on effective multi-drug treatment strategies tailored to different dormancy mechanisms.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!